Is ACADIA Pharmaceuticals Inc (ACAD) undervalued? · P/E 15, rev $957.8M
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
This page asks whether ACADIA Pharmaceuticals Inc (ACAD) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported ACAD revenue for 2024-12-31 was $957.8M. Net income was $226.5M. Revenue was up 314.6% from 2023-12-31 to 2024-12-31. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new ACAD 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare ACAD to the stock page model before you treat a low multiple as a gift.
Not investment advice.